• Acurx Pharmaceuticals reduced its shareholder meeting quorum from a majority to one-third (33.33%) of outstanding voting power.
• The board adopted the bylaw amendment effective Oct. 29, 2026, subject to exceptions under law, the certificate of incorporation or bylaws.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-120279), on October 29, 2026, and is solely responsible for the information contained therein.